# Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

> **NCT02215967** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Myeloma, Plasma-Cell
- Myeloma-Multiple

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells

## Key facts

- **NCT ID:** NCT02215967
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-12
- **Primary completion:** 2019-04-25
- **Final completion:** 2019-08-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215967, "Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02215967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*